Viking Therapeutics’ inventory doubles after corporate studies certain ends up in trial of weight-loss drug
Viking Therapeutics Inc.’s inventory soared 100% early Tuesday, after the corporate introduced certain effects from a Section 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that it’s growing in
